GleamWall
中文EN

ORIC Oric Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1796280 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-15.2%
TTM EPS YoY15.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.8%
ROA-39.1%
ROIC (approx.)-40.8%
Asset turnover—

Leverage & solvency

Liabilities / assets7.5%
Debt / equity0.00x
Current ratio11.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$109.82M$114.07M
SG&A expense$33.19M$28.82M
Operating income-$143.00M-$142.90M
Income tax$0$0
Net income-$129.47M-$127.85M
EBITDA-$141.78M-$141.79M
EPS (basic)-1.47-1.83
EPS (diluted)-1.47-1.83
Weighted avg. shares (diluted)87.79M69.73M
Balance sheet
Cash & equivalents$45.67M$59.90M
Short-term investments$235.82M$196.55M
Current assets$288.47M$262.25M
PP&E, net$2.42M$2.92M
Total assets$408.89M$274.14M
Current liabilities$20.42M$24.85M
Total liabilities$24.53M$31.02M
Shareholders' equity$384.36M$243.12M
Shares outstanding98.53M71.02M
Cash flow statement
Operating cash flow-$110.97M-$112.66M
Capital expenditure$712,000$1.19M
Free cash flow-$111.68M-$113.85M
Investing cash flow-$148.03M$22.14M
Financing cash flow$245.26M$126.55M
Depreciation & amortization$1.22M$1.11M
Stock-based compensation$25.04M$20.21M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.